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Abstract
Background
Schwannomas are rare tumours that pose a significant management challenge in the 
abdomen, retroperitoneum and pelvis. No data are available to inform management 
strategy.
Methods
A collaborative international cohort study, across specialist sarcoma units, was 
conducted to include adults with histopathologically-confirmed schwannomas within 
the abdomen, retroperitoneum, or pelvis presenting between 2000 and 2017.
Results
Of 485 patients across 12 centres, 38 (7·8%) were discharged without follow-up, 199 
(41·0%) underwent early resection, and 248 (51·1%) patients underwent radiological 
monitoring. Of these, 96/248 patients eventually underwent surgery (38·7%), giving an 
overall resection rate of 60·8% (295/485). At baseline, the median tumour volume was 
90·1cm3 (interquartile range: 26·5–262·0). The average growth rate was 10·5% per 
year (95% CI: 9·4% - 11·6%), and was consistent across the short- (within 2 years of 
diagnosis) and long-term (beyond 2 years, rho: 0·405, p=0·021). A decision to operate 
was more common in symptomatic patients (p<0·001) and rapidly growing tumours 
(>20% per year, p=0·025). R0/R1 resection was achieved in 91·6%. Kaplan-Meier long-
term recurrence rates after R0/R1 resection were 2% and 7% at 3 and 5 years, 
respectively.
Discussion
Specific recommendations include: indications for early surgery, prediction of growth 
from radiological monitoring, promotion of selective sub-macroscopic resection, and 
cessation of postoperative imaging surveillance.  
Introduction
Schwannomas are rare, usually benign nerve sheath tumours, typically composed of 
well-differentiated Schwann cells.1,2 The majority are solitary, sporadic, and 
represented by several different subtypes. A number are associated with genetic 
syndromes, such as neurofibromatosis type 2 or schwannomatosis.3 A decision to resect 
is considered on a case-by-case basis. There are no existing data to support superiority 
of early surgical intervention over a strategy of radiological monitoring. Furthermore, 
for patients that do undergo surgery, it is unclear if post-operative radiological 
surveillance is of benefit. Establishing evidence-based guidelines for management of 
these rare soft tissue tumours is challenging. 
The Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) 
represents an international collaboration of specialist sarcoma centres across the globe. 
The collective experience of this alliance captures the majority of patients with rare soft 
tissue tumours that undergo surgery worldwide.4 The primary aim of this study was to 
evaluate clinical, radiological, and histopathological features of abdominal, 
retroperitoneal, and pelvic schwannomas within this intercontinental collaborative 
group, to better understand the natural history of schwannomas, and make evidence-
based recommendations for future management. The principle objectives were to 
identify a practical method of predicting growth, stratify those that can be managed 
conservatively or surgically, and determine postoperative imaging surveillance.
Methods
Study design and approvals
A retrospective, international, multi-centre cohort study was undertaken according to a 
pre-specified protocol across high-volume specialist sarcoma units from North America, 
Europe, and Australia. All contributing centres were part of the Transatlantic 
Australasian Retroperitoneal Sarcoma Working Group.  Institutional Review Board 
approval and data sharing agreements were obtained according to local institutional 
policy in each centre prior to data collection. Ethical approval was obtained in countries 
where Local Research Ethics Committees deemed it a requirement. No specific funding 
was received for study conduct or data interpretation. This study was reported 
according the STROBE guidelines for observational studies.
Patients and settings
All adult patients (aged over 18 years) presenting with a primary abdominal, 
retroperitoneal and pelvic schwannoma from 1 January 2000 to 31 August 2017 were 
eligible for inclusion. Only confirmed schwannomas based upon biopsy or final 
histology of a resected specimen were included for analysis. Specialist sarcoma units 
have significant existing expertise in histopathological analysis of schwannomas, quality 
assuring patient inclusion. However, histological specimens were not further centrally 
reviewed for the purpose of this study. Patients undergoing radiological monitoring or 
resection were included. 
Data were extracted from Electronic Health Records, inpatient and outpatient clinical 
notes, imaging archives and clinical letters in each centre, depending on local 
availability and infrastructure. Data extraction included baseline demographics, mode 
and outcomes of diagnostics and imaging studies at presentation, choice and outcomes 
of management strategy (operative and non-operative), and mode and outcomes of 
surveillance imaging. Data were collated in each centre before being submitted for 
central analysis, fully-anonymised, using encrypted email accounts, in-line with Data 
Transfer Agreements between each collaborating centre and the coordinating centre 
(University Hospitals Birmingham UK). Follow-up continued for each patient until the 
end of the data collection period, death, or loss to follow-up, whichever was earliest. 
The primary outcome measure was tumour growth rate, assessed using volumetric 
assessment of sequential radiological scans (Computed Tomography (CT) or Magnetic 
Resonance Imaging (MRI)). The secondary outcome measures were the rate of surgical 
management, defined as a total or partial resection of the tumour through an abdominal 
incision, and for patients undergoing surgery: the high-grade post-operative 
complication rate, a composite measure including re-intervention, re-operation, single 
or multiple organ failure or death (grade 3 to 5); 5 the overall post-operative 
complication rate, defined as all deviations from the normal post-operative course 
(grade 1 to 5); the RO/R1 resection rate, defined as the absence of macroscopic residual 
disease at the circumferential resection margin; and the recurrence rate, defined as 
radiological evidence of residual or recurrent disease at the resection site.
Data management
Estimation of tumour volume
For the calculation of volume, we assumed that schwannomas would approximate the 
shape of a triaxial ellipsoid. As such, we estimated the volume from the reported tumour 
axial (x), coronal (y) and sagittal (z) dimensions using the formula V=4/3  (xyz). 
Z-score sensitivity analysis (tumour growth)
Whilst the majority of scans reported both the x and y-dimensions of the tumour, a 
considerable proportion (21.2%) did not report data on the z-dimension. Analysis of 
those tumours where all three dimensions were reported found that the average of the 
x- and y-dimensions correlated with the z-dimension (Spearman’s rho=0.920), with an 
average difference of <1cm (mean=0.88). As such, missing z-dimensions were replaced 
with the average of the x- and y-dimensions to maximise the included sample size. To 
test the effect of this assumption on the primary outcome of the tumour growth rate, a 
sensitivity analysis was performed excluding those with missing z-dimensions to 
measure the influence of this assumption on the conclusions of the analysis.
Inter-scan intervals
A minimum interval of 60 days between consecutive scans was set, in order to prevent 
artificial inflation of the sample size. Where a patient had a CT and MRI scan within a 
60-day period, the MRI was excluded. Where both scans were of the same type (e.g. two 
CT scans), the earlier one within the 60-day period was excluded. 
Statistical methods
Initially, the tumour volumes recorded at the first available scan (‘baseline scan’) for 
each patient were compared across a range of factors. Upon visualising the data in a 
density plot, the distribution of tumour size was found to be highly positively skewed; 
hence a non-parametric approach was used, with comparisons made by Mann-Whitney 
or Kruskal-Wallis tests, and data summarised using medians and interquartile ranges 
(IQRs).
The change over time in tumour volume was assessed using a general linear model. 
Since it followed a skewed distribution and preliminary analysis suggested that changes 
in tumour volume was non-linear, values were log10-transformed. The timing of each 
scan, relative to the first scan for that patient, was set as a continuous covariate. The 
patient ID was set as a categorical factor, allowing each patient to have a different 
intercept, to account for the inter-patient variability in baseline tumour volume. The 
coefficients from the resulting model were then anti-logged, and converted into 
percentage increases in tumour volume per year. 
As well as assessing the tumour growth rate for the cohort as a whole, the model was 
also repeated for each patient in whom at least three scans were available. The resulting 
gradients were then compared across a range of factors, using Mann-Whitney and 
Kruskal-Wallis tests, to identify predictors of tumour growth rates.
Rates of surgery were analysed using a time-to-event approach, in order to account for 
the timing of surgery, and the different durations of follow up across the cohort. The 
start of follow up was set to the earliest recorded date for each patient, be this the point 
of referral, provisional diagnosis or the first CT/MRI scan. Those that did not undergo 
surgery were censored on the 31st August 2017. The timing of surgery was visualised 
using a Kaplan-Meier curve, whilst Cox regression models were used to compare the 
rates of surgery across a range of factors. In those that underwent R0/R1 resections, 
and entered post-operative surveillance, a similar analysis was then used to estimate 
the rates of tumour recurrence.
Predictors of post-operative complications were then assessed. Categorical variables 
were analysed using Fisher’s exact tests for dichotomous variables, or Chi-square tests 
for those with more than two categories. Ordinal variables were analysed using Mann-
Whitney tests. The analysis was then repeated to identify predictors of high-grade 
complications (Clavien-Dindo grade 3 to 5). 5
All analyses were performed using IBM SPSS 22 (IBM Corp. Armonk, NY), with an alpha 
level of 5% (P<0.05) used throughout. Cases with missing data were excluded on a per-
analysis basis. The numbers of patients included in each analysis were reported in the 
tables, to allow for such exclusions to be identified.
Results
Patient demographics
Data were available (see Table 1) for a total of 485 patients (56.1% female), with a 
median age at diagnosis of 54 years (IQR: 41 – 64 years). Data were included from 12 
centres across North America, Europe and Australia (Supplementary Table 1). The 
mode of presentation was approximately equally split between incidental findings 
(51.2%) and symptomatic patients (48.8%), with the majority of tumours in the 
retroperitoneum (50.5%). The type of schwannoma was poorly recorded, only being 
available in 110 cases (22.7%), with the majority of these being cellular (50.0%) or 
ancient (42.7%). No schwannomas displayed malignant transformation within this 
cohort. Ten patients reported a genetic predisposition (neurofibromatosis type II and 
schwannomatosis). Diagnosis was most commonly made by pre-operative core biopsy 
(64.4%, N=313). 
Brief overview of management
The breakdown of the approaches to tumour management is reported in Figure 1. In 38 
(7.8%) patients, only a single scan was performed after presentation, hence these 
patients were assumed to have been discharged at diagnosis. Surgery was performed 
within six months of the initial consultation for 199 (41.0%) patients, who were 
classified as the early surgery group. The remaining 248 (51.1%) underwent 
radiological monitoring, of whom 96 (38.7%) were eventually treated surgically.
Scan data
Of the 485 patients in the cohort, a total of 424 (87.4%) had data for at least one scan 
during the study period from which a tumour volume could be estimated, with a total of 
1201 scans performed between 1 January 2000 and 31 August 2017. After excluding 
109 scans that were within 60 days of a subsequent scan, a total of 1092 scans in these 
424 patients were available for analysis. Of these, 188 patients contributed only a single 
scan, and so were excluded from longitudinal analysis of tumour growth. The remaining 
236 patients contributed a total of 904 scans to the analysis (median: 3, IQR: 2-5 scans), 
over a median of 20 months (IQR: 6 – 47 months) of follow up.
Initial tumour size
In baseline scans, the median tumour volume was 90.1cm3 (IQR: 26.5 – 262.0). Tumours 
were significantly larger in male patients, with a median of 112.7cm3, compared to 
73.5cm3 in females (p=0.005, Table 3). Tumour size also differed significantly by 
location (p<0.001), with pelvic tumours being the largest, and abdominal tumours the 
smallest (median 124.7 vs. 20.9cm3). Cellular schwannomas were significantly larger 
than ancient schwannomas (median: 264.9 vs. 66.7cm3, p=0.002). ASA grade at referral 
was inversely associated with tumour size, with a median of 151.3cm3 for ASA1, 
compared to 87.0cm3 for ASA3-4 (p=0.001). No significant associations between tumour 
size and either age (p=0.254) or type of presentation (p=0.767) were detected. 
Tumour growth
Longitudinal analysis of tumour growth was based on the 236 patients (904 scans) with 
more than one scan during the study period. Including all scans in a single model, we 
found that tumour volume increased significantly over time (p<0.001), with an 
estimated gradient of 10.5% per year (95% CI: 9.4% - 11.6%). Due to the large sample 
size, it was difficult to clearly demonstrate this effect graphically; hence three 
approaches were used. Figure 2a displays the percentage change from the first scan to 
all subsequent tumour measurements, along with the trend line produced by the 
regression model. Figure 2b shows the pooled average tumour volume within intervals 
of the follow up period. Figure 3 shows the individual trajectories of tumour volume in 
those patients with more than five scans, split by the size of the tumour at baseline.
In 192/904 (21.2%) scans included in the analysis, the z-dimension of the tumour was 
unavailable, and so was estimated based on the x and y dimension. A sensitivity analysis 
in which these scans were excluded returned similar results, with an estimated growth 
rate of 11.0% per year (95% CI: 9.8% - 12.2%, p<0.001) over 712 included scans.
The rate of tumour growth was also estimated at a patient level for the 146 patients 
with data available for at least three scans. Using this approach, the average tumour 
growth rate was found to be similar to utilising all scans in a single model (described 
above), at a median of 10.0% per year (IQR: 1.4% - 18.9%). Tumour volume was found 
to be relatively stable over time (i.e. ±2% per year) in a small number of patients (n=18, 
12.3%), and to decline over time in 25 (17.1%) patients. However, the majority of 
patients saw an increase in tumour size, with 69 (47.2%) having a gradient between 3-
20% per year, and 34 (23.2%) growing by >20% per year. None of the factors 
considered were found to be significantly predictive of growth rate (Table 3). 
Short and long-term growth rates of tumours were then compared. Growth rates were 
estimated separately for the first two years of follow up, and over subsequent scans for 
each patient. A total of 32 patients had at least three scans in both periods, and were 
included in the analysis. For these, the growth rate over the first two years was found to 
be significantly correlated with the subsequent growth rate (rho: 0.405, p=0.021, 
Figure 4a). Bland-Altman analysis (Figure 4b) found no significant difference between 
the short- and long-term growth rates, with a mean difference of 2.7 (standard 
deviation: 22.9) percentage points per year (p=0.505).  However, there was 
considerable variability within the pairs of growth rates, with a 95% prediction interval 
of approximately ±45 percentage points per year. 
The tumours were then divided into those with slower (≤10% per year, N=16) and 
faster (>10% per year, N=16) growth rates over the initial two years of follow up. Of 
those with faster growth initially, 56% (9/16) retained a >10% growth rate over the 
subsequent period of follow up, compared to 25% (4/16) of those with a slower initial 
growth rate.
Decision to operate
The entire cohort of N=485 had a median of 59 months of follow-up (Kaplan-Meier 
estimate of potential follow-up), during which time 295 patients underwent surgery. Of 
these, N=199 were classified as early surgery, occurring within six months of diagnosis, 
after a median of 67 days (IQR: 36-107). For those patients that entered radiological 
monitoring (N=248), N=96 were eventually treated surgically, giving Kaplan-Meier 
estimated surgery rates of 20.4%, 31.3% and 37.9% at 1, 3 and 5 years after diagnosis, 
respectively (Figure 5). For those that underwent surgery, the reason for operating was 
recorded for 276 (93.6%), with the most common reasons being due to the patient 
being symptomatic (40.2%) or due to an uncertain diagnosis (35.5%). Of those in whom 
surgery was not performed, reasons were recorded in 180 (94.7%) patients, with the 
decision most commonly due to a patient being asymptomatic and stable (42.8%) or 
asymptomatic with a risk of major nerve injury (23.9%). A further breakdown of these 
reasons is reported in Supplementary Table 2.
Factors associated with decision to operate
Surgery was found to be significantly more common in patients with symptomatic vs. 
incidental presentation, with crude rates of 68.9% vs. 52.7%, respectively (p<0.001). 
Tumours with major nerve involvement were significantly less likely to be resected 
(55.2% vs. 76.2%, p=0.001). There was a trend towards a higher rate of surgery in 
abdominal tumours (66.1% vs. 54.3% in pelvic tumours, p=0.052) and in patients with a 
younger age at presentation (72.2% vs. 56.3% in <40 vs. 65+ years, p=0.051), although 
neither of these comparisons reached statistical significance. A significant association 
between surgery and the tumour growth rate was also detected (p=0.003). Those 
tumours with the fastest increases in volume (>20% per year) had the highest rate of 
surgery at 41.2%, compared to 5.6% in stable (±2% per year) tumours (p=0.025, Table 
4).
Intra-operative factors and post-operative outcomes
Further details of the 295 patients that underwent surgery are reported in 
Supplementary Table 3. Post-operative complication data were available for 221 
patients, of whom 61 (27.6%) developed complications. The complication grade could 
be derived for 52 of these patients, with 18 (8.5% of patients undergoing surgery) found 
to have high-grade (grade 3-5) complications. Associations between a range of factors 
and complication rates are reported in Table 5a/b. This analysis found significantly 
higher complication rates in faster growing tumours (p=0.033), in those originating 
from a named nerve (p=0.003), with a major nerve resection/transection (p=0.002), 
and in cases with vascular resection (p<0.001). Analysis of the rates of high-grade 
complications found only vascular resection to be significant (p=0.001). Post-operative 
length of stay was recorded in 283 (95.9%) operated patients, with a median of 6 days 
(IQR: 4 – 9), and 23 (7.8%) patients staying longer than two weeks. Moderate to severe 
long-term impairment was induced by major nerve division (seven femoral and 11 
lumbosacral) and one operative death occurred after attempted repair of a post-
operative enterocutaneous fistula. 
Resection margin
Preoperative cross-sectional imaging was recorded in 294 patients, of whom an R0/R1 
resection was predicted in 273 (92.9%). The final resection status was unavailable in 
two of these patients, with 262 (96.7%) of the remainder ultimately achieving an R0/R1 
resection, and nine (3.3%) having an unplanned R2 resection. Of the 24 patients where 
an R2 resection was predicted, the final resection status was recorded in 16, of whom a 
single patient (6%) received an unplanned R0/R1 resection.
Post-operative surveillance
Of the 263 patients who underwent an R0/R1 resection, 124 (47.1%) entered a post-
operative surveillance programme. Of these, 57 (45.6%) received only a single 
surveillance scan, with a maximum of ten scans, over a median surveillance period of 19 
months (IQR: 7 – 39). Residual disease was detected at the first post-operative scan in 
four (3.2%) patients. After excluding these, a total of four patients developed recurrence 
during post-operative surveillance at 12, 12, 24 and 57 months, giving Kaplan-Meier 
estimated long-term recurrence rates of 2% and 7% at 3 and 5 years, respectively.
Of the 24 patients who had an R2 resection, 12 had data available for post-resection 
surveillance. The first scan was performed a median of 7 months (IQR: 5 – 15) after 
resection, with the median tumour volume being 41.2 cm3 (IQR: 2.1 – 163.2). Multiple 
scans were available for ten patients, who contributed a total of 39 scans, with a 
maximum of six scans per patient and a maximum follow up time of 48 months. No 
significant post-resection tumour growth was detected in this cohort (p=0.536), with an 
average estimated growth rate of 2.8% per year (95% CI: -6.1%, 25.9%).
Discussion
The growth characteristics of schwannomas were previously unknown, leading to a 
great deal of uncertainty in optimal clinical management. All existing literature on 
schwannomas is confined to case studies or small single-centre case series.2,6-11 The 
inclusion of all eligible schwannomas in a single growth model found tumour volume to 
increase significantly over time. This steady expansion has significant consequences if 
the tumour is critically placed against anatomical structures.  Surgical morbidity in the 
near term needs to be considered against the potential longevity of the patient, possible 
heightened complexity of future resection, and preservation of function. 
On an individual basis, there is a huge variability in size at presentation and subsequent 
rate of expansion. Tumours of all sizes at presentation appeared to retain the ability to 
grow with a highly individualised trajectory, ranging from largely stable with some 
exhibiting a prolonged period of stability to growing at >20% per annum. For those 
patients without clear indication for immediate resection, the unpredictability of 
tumour growth at presentation impacts informed decision-making regarding timing of 
surgery. Practical guidance is therefore required, and this can only be based upon serial 
cross-sectional images to obtain an indication of the tempo of tumour growth over time. 
In patients without a clear indication for immediate resection, the future growth 
trajectory can be cautiously predicted after three scans over a two-year period. No 
other factors had a bearing on tumour growth, including anatomical location and 
interestingly, histological subtype, with the classically indolent ancient schwannoma 
expanding at a similar rate to the main cohort.
The spectrum of disease, in terms of anatomical location, size at presentation and 
growth characteristics was broad. Pelvic tumours tended to be the largest, where occult 
expansion can occur until eventually constrained by bony contours or discovered 
coincidentally. Histological sub-characterisation was not widely described; however, of 
the two major subtypes, cellular schwannomas were found to be significantly larger at 
presentation than ancient schwannomas. Interestingly, size at presentation was found 
to be negatively correlated with ASA grade, perhaps due to the greater propensity for 
more co-morbid patients to undergo cross-sectional imaging and therefore discover 
asymptomatic lesions at an earlier stage.
Symptomatic presentation was one of the main drivers for resection, although patients 
with major nerve involvement were significantly less likely to undergo surgery, 
presumably due to concerns regarding associated morbidity. Those exhibiting rapid 
expansion (>20% increase) and younger patients were most likely to undergo resection. 
Abdominal schwannomas also tended towards higher rates of resection, compared to 
pelvic lesions. Difficulty in establishing a preoperative diagnosis with biopsy, due to 
surrounding structures, may also have contributed to increased levels of resection for 
abdominally placed tumours.
For the uninitiated, the benign nature of schwannomas can falsely reassure the 
operating surgeon and patient that resection will be a relatively straightforward 
endeavour. However, these tumours are hard, unyielding, vascular, and firmly adherent 
to surrounding critical structures. Operative morbidity is high, where risk factors for 
complications were faster-growing tumours, involvement of a major nerve, or division 
of a named artery. Surprisingly, location of the tumour was not associated with a higher 
risk of complication. Large schwannomas in the pelvis are classically associated with 
significant morbidity and blood loss, and the equivalence of operative risk is likely to 
reflect selective resection practice. 
Anticipated (planned) and all R2 resections were associated with a higher complication 
rate. If more aggressive surgery were performed to avoid incomplete resections 
entirely, the overall complication rate may have been even higher, from expected 
division of major nerves and vessels. Moderate to severe long-term impairment was 
seen to be induced by major nerve division. Planned R2 resection, where an R0/R1 
resection would necessitate major nerve or artery division, would seem a reasonable 
option to minimise long-term morbidity. Preoperative planning with the aid of cross-
sectional imaging can be used to counsel patients on the likelihood of an R0/R1 or R2 
resection and the potential implications that this may have.
In the majority of contributing institutions, post-resection surveillance was offered to 
patients as a default policy, along similar lines to comparable sarcoma resections. With 
such a low incidence of recurrence, post-operative surveillance imaging should not be 
routinely recommended. If imaging is thought to be required, consideration of a one-off 
baseline scan to exclude residual disease at three months post resection may be of 
value. The value of post-operative surveillance remains debatable with an average 
estimated growth rate of 2.8% per year. No further operative intervention was 
performed following R2 resection during the period of the study. A pragmatic approach 
is recommended with surveillance balanced with the patient’s wishes and the 
knowledge that further attempts at resection risks the morbidity that the incomplete 
resection was designed to avoid at the first operation.
Limitations
As with any retrospective study, selection and measurement biases were evident. 
Selection bias was minimised by including all operated and non-operative patients 
referred to sarcoma services during the time window, although the burden of disease 
that was not referred to these centres (e.g. locally managed, not detected) remains 
unmeasured. Not all data fields were complete for each patient, leading to a moderate 
level of data absence for some fields. This was a particular issue for the z-dimensions of 
tumours, which was not recorded in over a fifth of scans. However, this was mitigated 
by estimating the volume based on the remaining dimensions, with sensitivity analysis 
indicating that this had minimal impact on the analysis of tumour growth.
Although patients were often followed up for prolonged periods, there was inevitable 
attrition bias due to patients moving or being lost to follow-up. Histological sub-
classification of schwannomas was not universally performed, which prevented 
comment on the growth characteristics of some of the rarer subtypes, such as 
melanocytic schwannomas.
Recommendations for surgical management of abdominal, retroperitoneal, and pelvic
schwannomas:
1. Early indications for surgery include symptomatic tumour at presentation, 
diagnostic uncertainty and existing evidence of rapid expansion or patient 
preference after adequate counselling.
2. Where a clear indication for surgery at presentation exists, then surgery should 
proceed with adequate patient counselling, and consideration given to a planned 
R2 resection if major nerves or vessels would otherwise need to be sacrificed.
3. In the absence of an indication for early surgery, diagnosis of a schwannoma 
should be confirmed on biopsy and the patient enrolled in to a programme of 
radiological monitoring for at least 2-years in order to predict individualised 
tumour growth characteristics. After identification of growth characteristics, 
multi-disciplinary discussion should then occur to consider future resectability 
and likely induced morbidity of surgery, coupled with patient age, wishes and 
specific tumour location.
4. Post-operative surveillance imaging for patients with R0/R1 resected 
schwannomas holds little benefit beyond a baseline scan and should not be 
routinely recommended.
5. Post-operative surveillance imaging after R2 resection should be considered on a
pragmatic basis.
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Table 1 – Patient demographics
Data are reported as N (%), or as median (IQR), as applicable. “Total N” represents the 




Age at Diagnosis (Years) 485 54 (41 - 64)
Gender (Female) 485 272 (56.1%)


















Major Nerve Involvement 306 67 (21.9%)





Age at Diagnosis (Years) 0.254
< 40 97 91.2 (27.0 - 253.8)
40 - 54 121 90.3 (24.6 - 235.3)
55 - 64 99 110.2 (31.6 - 364.7)
65+ 107 67.3 (21.2 - 198.5)
Gender 0.005
Female 243 73.5 (20.6 - 217.6)
Male 181 112.7 (36.3 - 402.2)
ASA (at Referral) 0.001
1 119 151.3 (49.4 - 335.1)
2 97 65.4 (25.7 - 197.3)
3-4 64 87.0 (20.4 - 167.2)
Presentation 0.767
Incidental 211 89.8 (36.3 - 224.1)
Symptomatic 203 92.1 (24.1 - 305.8)
Location of Schwannoma <0.001
Abdominal 52 20.9 (6.8 - 59.6)
Pelvis 161 124.7 (37.5 - 335.1)
Retroperitoneal 211 90.6 (31.8 - 261.0)
Type 0.002
Ancient 36 66.7 (27.7 - 224.9)
Cellular 50 264.9 (97.4 - 578.8)
Other 8 147.7 (32.5 - 364.2)
Major Nerve Involvement 0.249
No 200 53.9 (21.1 - 170.8)
Yes 60 103.1 (19.1 - 231.0)
Data are reported as median (IQR), with p-values from Mann-Whitney tests or Kruskal-
Wallis tests, as applicable. Bold p-values are significant at p<0.05. *The tumour volume at 
the first scan for which data were recorded.




 Volume per Year p-Value
Age at Diagnosis (Years) 0.450
< 40 32 13.8% (2.8%, 21.4%)
40 - 54 48 9.7% (2.4%, 16.9%)
55 - 64 32 5.7% (0.4%, 15.1%)
65+ 34 8.8% (-0.9%, 20.2%)
Gender 0.360
Female 74 11.4% (2.3%, 20.2%)
Male 72 8.6% (0.4%, 17.2%)
ASA (at Referral) 0.731
1 31 11.4% (1.7%, 21.2%)
2 21 13.0% (5.0%, 20.2%)
3-4 11 9.2% (-0.9%, 18.7%)
Presentation 0.181
Incidental 85 8.9% (0.8%, 16.4%)
Symptomatic 59 12.6% (3.1%, 21.0%)
Location of Schwannoma 0.053
Abdominal 17 2.3% (-4.1%, 8.8%)
Pelvis 60 11.0% (4.1%, 18.9%)
Retroperitoneal 69 11.3% (0.0%, 20.2%)
Type of Schwannoma 0.924
Ancient 5 6.4% (1.9%, 14.4%)
Cellular 13 10.0% (1.7%, 21.0%)
Major Nerve Involvement 0.654
No 41 9.2% (1.8%, 28.3%)
Yes 18 11.9% (5.0%, 21.5%)
Initial Tumour Volume (cm3)* 0.306
< 25 37 8.7% (-0.1%, 14.6%)
25 - 99 40 11.5% (1.6%, 28.2%)
100 - 299 39 11.7% (2.6%, 19.0%)
300+ 30 8.7% (0.8%, 14.4%)
The average rate of change in tumour size was estimated for each patient by producing 
individual regression models, with the log10-transformed tumour size set as the dependent 
variable. Only those patients with at least three scans (N=146) were included in the 
analysis. The gradients from the resulting models were then converted into percentage 
changes per year, which were summarised as median (IQR). Comparisons between groups 
were performed using Mann-Whitney tests and Kruskal-Wallis tests, and bold p-values are 
significant at p<0.05. *The tumour volume at the first scan for which data were recorded.







Age at Diagnosis (Years) 0.154
< 40 108 78 (72.2%) - -
40 - 54 141 83 (58.9%) 0.73 (0.54 - 1.00) 0.051
55 - 64 117 67 (57.3%) 0.77 (0.56 - 1.07) 0.125
65+ 119 67 (56.3%) 0.72 (0.52 - 1.00) 0.051
Gender 0.138
Female 272 175 (64.3%) - -
Male 213 120 (56.3%) 0.84 (0.66 - 1.06) 0.138
ASA (at Referral) 0.147
1 133 86 (64.7%) - -
2 114 86 (75.4%) 1.31 (0.97 - 1.77) 0.074
3-4 74 56 (75.7%) 1.30 (0.93 - 1.82) 0.129
Presentation <0.001
Incidental 239 126 (52.7%) - -
Symptomatic 228 157 (68.9%) 1.53 (1.21 - 1.93) <0.001
Location of Schwannoma 0.050
Abdominal 62 41 (66.1%) - -
Pelvis 175 95 (54.3%) 0.70 (0.48 - 1.00) 0.052
Retroperitoneal 242 155 (64.0%) 0.93 (0.66 - 1.31) 0.660
Type of Schwannoma 0.827
Ancient 47 36 (76.6%) - -
Cellular 55 45 (81.8%) 1.13 (0.73 - 1.76) 0.578
Other 8 5 (62.5%) 0.95 (0.37 - 2.41) 0.908
Major Nerve Involvement 0.001
No 239 182 (76.2%) - -
Yes 67 37 (55.2%) 0.56 (0.39 - 0.80) 0.001
Initial Tumour Volume (cm3)* 0.577
< 25 102 57 (55.9%) - -
25 - 99 122 71 (58.2%) 1.08 (0.76 - 1.54) 0.652
100 - 299 108 59 (54.6%) 0.99 (0.69 - 1.43) 0.973
300+ 92 56 (60.9%) 1.25 (0.87 - 1.81) 0.231
Tumour Growth (% per Year)** 0.003
<-2% (Reduction) 25 4 (16.0%) 4.04 (0.45 – 36.3) 0.212
-2% to 2% (Stable) 18 1 (5.6%) - -
3% to 20% (Increase) 69 9 (13.0%) 2.48 (0.31 – 19.6) 0.390
>20% (Increase) 34 14 (41.2%) 10.2 (1.33 – 77.7) 0.025
Crude rates represent the total proportion of patients that underwent surgery during the 
follow up period. Hazard ratios and p-values are from univariable Cox regressions, which 
account for the period of follow up and timing of surgery, with HRs >1 representing a 
higher rate of surgery in the stated group. Bold p-values are significant at p<0.05. *The 
tumour volume at the first scan for which data were recorded. **Tumour growth was 
estimated using patient-level regression models for those with three or more available 
scans.
Table 5a – Predictors of complications after surgery (part 1)







Age at Diagnosis (Years) 0.356* 0.802*
< 40 61 13 (21.3%) 58 5 (8.6%)
40 - 54 60 20 (33.3%) 57 4 (7.0%)
55 - 64 51 12 (23.5%) 49 5 (10.2%)
65+ 49 16 (32.7%) 48 4 (8.3%)
Gender 0.067 0.319
Female 128 29 (22.7%) 122 8 (6.6%)
Male 93 32 (34.4%) 90 10 (11.1%)
ASA (at Referral) 0.699* 0.855*
1 79 22 (27.8%) 75 7 (9.3%)
2 69 18 (26.1%) 67 7 (10.4%)
3-4 40 13 (32.5%) 39 3 (7.7%)
Presentation 0.760 0.804
Incidental 105 27 (25.7%) 103 9 (8.7%)
Symptomatic 111 31 (27.9%) 106 8 (7.5%)
Location of Schwannoma 0.551 0.766
Abdominal 23 6 (26.1%) 23 2 (8.7%)
Pelvis 78 25 (32.1%) 77 8 (10.4%)
Retroperitoneal 116 29 (25.0%) 109 8 (7.3%)
Type of Schwannoma 0.111 0.729
Ancient 32 13 (40.6%) 28 3 (10.7%)
Cellular 42 8 (19.0%) 41 3 (7.3%)
Other 5 2 (40.0%) 4 0 (0.0%)
Major Nerve Involvement 0.511 0.305
No 125 34 (27.2%) 122 14 (11.5%)
Yes 32 11 (34.4%) 29 1 (3.4%)
Initial Tumour Volume (cm3)** 0.093* 0.305*
< 25 36 5 (13.9%) 36 2 (5.6%)
25 - 99 60 14 (23.3%) 58 4 (6.9%)
100 - 299 49 16 (32.7%) 48 5 (10.4%)
300+ 43 12 (27.9%) 40 4 (10.0%)
Tumour Growth (% per Year)*** 0.033* -
<-2% (Reduction) 4 0 (0.0%) 4 0 (0.0%)
-2% to 2% (Stable) 0 - 0 0 (0.0%)
3% to 20% (Increase) 6 1 (16.7%) 6 0 (0.0%)
>20% (Increase) 12 5 (41.7%) 12 0 (0.0%)
High grade complication is defined as a Clavien-Dindo grade of 3+. Clavien-Dindo grades were not available 
for N=9 patients, hence these were excluded from the analysis of high grade complications. p-Values are from 
Fisher’s exact test/Chi-square test for comparisons of two/more than two groups, unless stated otherwise 
Bold p-values are significant at p<0.05. *p-Value from Mann-Whitney test, as the factor is ordinal. **The 
tumour volume at the first scan for which data were recorded. ***Tumour growth was estimated using 
patient-level regression models for those with three or more available scans. 
Table 5b – Predictors of complications after surgery (part 2)







Reason for Operating 0.475 0.658
Symptomatic 81 19 (23.5%) 78 5 (6.4%)
Uncertain diagnosis 72 20 (27.8%) 71 6 (8.5%)
Enlarging lesion 31 7 (22.6%) 30 2 (6.7%)
Anatomical obstruction / compression 13 6 (46.2%) 13 2 (15.4%)
Other 12 4 (33.3%) 12 2 (16.7%)
Originating from a Named Nerve 0.003 1.000
No 109 21 (19.3%) 107 8 (7.5%)
Yes 54 23 (42.6%) 47 3 (6.4%)
Major Nerve Division or Resection 0.002 0.403
No 131 30 (22.9%) 125 8 (6.4%)
Yes 28 15 (53.6%) 26 3 (11.5%)
Vascular Division or Resection <0.001 0.001
No 79 15 (19.0%) 79 2 (2.5%)
Yes 27 16 (59.3%) 27 7 (25.9%)
Intention of Surgery 0.085 1.000
R0/R1 203 52 (25.6%) 197 16 (8.1%)
R2 17 8 (47.1%) 14 1 (7.1%)
Margin 0.121 1.000
R0/R1 194 50 (25.8%) 189 16 (8.5%)
R2 21 9 (42.9%) 18 1 (5.6%)
High grade complication is defined as a Clavien-Dindo grade of 3+. Clavien-Dindo grades were not available 
for N=9 patients, hence these were excluded from the analysis of high grade complications. p-Values are from 
Fisher’s exact test/Chi-square test for comparisons of two/more than two groups, unless stated otherwise 
Bold p-values are significant at p<0.05. 




Brigham and Women’s Hospital/Dana-Farber Cancer Institute. Boston, USA 26
Emory University Hospital. Atlanta, USA 83
Institute of Oncology Ljubljana. Ljubljana, Slovenia 21
Istituto Nazionale dei Tumori. Milan, Italy 37
Mayo Clinic. Jacksonville, USA 23
Moffitt Cancer Centre. Tampa, USA 13
Mount Sinai Hospital. Toronto, Canada 63
Netherlands Cancer Institute. Amsterdam, The Netherlands 10
Ottawa Hospital Research Institute. Ottawa, Canada 55
Peter MacCallum Cancer Centre. Melbourne, Australia 17
Queen Elizabeth Hospital. Birmingham, UK 52
Royal Marsden Hospital. London, UK 85




Reason for Not Operating 180
Stable and asymptomatic 77 (42.8%)
Risk of major nerve injury and asymptomatic 43 (23.9%)
Asymptomatic 22 (12.2%)
Complexity of resection 13 (7.2%)
Co-morbidity 8 (4.4%)
Other 17 (9.4%)
Reason for Operating 276
Symptomatic 111 (40.2%)
Uncertain diagnosis 98 (35.5%)
Enlarging lesion 33 (12.0%)
Anatomical obstruction / compression 14 (5.1%)
Other 20 (7.2%)
Data are reported as N (%), and are based on the N=295 (60.8%) who underwent surgery, 
or the N=190 (39.2%) that did not. “Total N” represents the number of patients for whom 
data were recorded for the stated factor. 




Schwannoma Originating from a Named Nerve 186 69 (37.1%)
Major Nerve Division or Resection 171 31 (18.1%)
Vascular Division or Resection 124 39 (31.5%)






Any Complication 221 61 (27.6%)
Clavien-Dindo Grade 212






Post-operative Length of Stay (Days) 283 6 (4 – 9)
Data are reported as N (%) or median (IQR), and are based on the N=295 (60.8%) who 
underwent surgery, unless stated otherwise. “Total N” represents the number of patients 
for whom data were recorded for the stated factor.
Figure 1 – Flow diagram of overall patient management 
Figure 2 – Change over time in tumour volume. Figure 2A shows the percentage differences in tumour 
volume between the first scan for a patient to all subsequent scans. The y-axis was truncated at a 500% 
increase to improve scaling, resulting in N=7 scans being excluded from the plot. Figure 2B shows the 
geometric mean tumour volume within percentiles of the follow up time. Each point is based on between 53 
and 66 scans, with the exception of the initial scans (at time=0, N=236), and whiskers represent 95% 
confidence intervals. For both plots, the trendline is from the general linear model described in text.
Figure 3 – Plots of tumour volume trajectories for patients with more than five scans. Patients with more 
than five scans were included in the plots. Due to the large variability in tumour volumes at referral, and the 
number of trajectories being plotted, patients were divided over two plots, based on the initial tumour 
volume. Figure 3A includes those with initial tumour volume <120cm3 (161 scans in 22 patients), with the 
remainder in Figure 3B (165 scans in 22 patients). Both plots use a logarithmic y-axis to improve scaling 
Figure 4 – Comparisons of short and long term growth rate. The plots show the data for the N=32 patients 
that had at least three scans in the first two years, and at least three subsequent scans. Figure 4A is a 
comparison of the gradients over these two periods, with the broken line plotted at y=x. Figure 4B is a 
Bland-Altman plot of growth rates in the first two years, and across subsequent scans. The solid red line 
represents the mean difference between these two growth rates, whilst broken lines are 95% prediction 
intervals. pp=percentage points. 
Figure 5 – Kaplan-Meier curve of the time to surgery in the radiologically monitored group. Only patients 
undergoing radiological monitoring (N=248) were included in the analysis, hence those treated surgically 
within six months of diagnosis (broken line) or discharged at diagnosis were excluded. 
